Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEO 158968 in Subjects With Gout Flares
NCT06444867Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Jan 2025
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of LEO 158968 in acute gouty arthritis, sponsored by LEO Pharma. Primary endpoint: Number of Participants with a Patient-reported Pain Intensity Score of 0 or 1 as Assessed by the 5-point Likert Scale at Day 4. Started Jan 2025; status: completed.
02
Drugs
LEO 158968
03
Conditions
acute gouty arthritis
Beyond the preview
Go deeper on NCT06444867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06444867.